EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tci Gene's Enterprise Value is NT$1,157.7 Mil.
Tci Gene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$14.7 Mil. Therefore, Tci Gene's EV-to-FCF for today is 78.85.
The historical rank and industry rank for Tci Gene's EV-to-FCF or its related term are showing as below:
ROCO:6879'
s EV-to-FCF Range Over the Past 10 Years
Min: 11.04 Med: 22.69 Max: 100.8
Current: 79.39
During the past 5 years, the highest EV-to-FCF of Tci Gene was 100.80. The lowest was 11.04. And the median was 22.69.
ROCO:6879's EV-to-FCF is ranked worse than 84.04% of 376
companies
in the Biotechnology industry
Industry Median: 9.49
vs ROCO:6879: 79.39
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-22), Tci Gene's stock price is NT$78.50.
Tci Gene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.440. Therefore, Tci Gene's PE Ratio for today is 178.41.
Tci Gene EV-to-FCF Historical Data
The historical data trend for Tci Gene's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tci Gene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tci Gene's EV-to-FCF falls into.
Tci Gene's current Enterprise Value is NT$1,157.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$14.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tci Gene's share price for today is NT$78.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tci Gene EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Tci Gene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6879 has been successfully added to your 